




(a) Brain tissue (cortex) in preclinical studies




(b) Brain tissue (caudate nucleus) in preclinical studies




(c) Brain tissue (hippocampus) in preclinical studies




(d) Brain tissue (hypothalamus) in preclinical studies




(e) Brain tissue (striatum) in preclinical studies




(f) Brain tissue (pineal gland) in preclinical studies




(g) Brain tissue (midbrain) in preclinical studies




(h) Brain tissue (unspecified) in preclinical studies




(i) Microdialysis (cortex) in preclinical studies




(j) Microdialysis (amygdala) in preclinical studies




(k) Microdialysis (hippocampus) in preclinical studies




(l) Microdialysis (hypothalamus) in preclinical studies



(m) Microdialysis (nucleus accumbens shell) in preclinical studies



(n) Microdialysis (striatum) in preclinical studies



**Figure S1.** Count of experimental groups reporting significant increases, decreases, or non-significant changes in the levels of the biomarkers by non-invasive brain stimulation. (a-h) and (i-n) from the individual regions of brain tissue and microdialysis in preclinical studies, respectively. \*: biomarkers in the serotonin pathway. Tryptophan refers to total tryptophan when not specified.